

PRESCRIBING INFORMATION

Cyanocobalamin Injection USP

1000 mcg/mL

Sterile Solution for Intramuscular or Deep subcutaneous injection

Hematopoietic

Eugia Pharma Inc.
3700 Steeles Avenue West, Suite 402
Woodbridge, Ontario, L4L 8K8
Canada

Date of Preparation:
May 18, 2023

Control Number: 274394

Cyanocobalamin Injection USP

1000 mcg/mL

Sterile Solution for Intramuscular or Deep subcutaneous injection

ACTION AND CLINICAL PHARMACOLOGY

Vitamin B₁₂ is a group of cobalt-containing B complex vitamins, also known as cobalamins, synthesized by microorganisms. Cyanocobalamin and hydroxocobalamin are the principal forms of Vitamin B₁₂ in clinical use. They have equivalent Vitamin B₁₂ activity.

In humans; exogenous source of Vitamin B₁₂ is required for nucleoprotein and myelin synthesis, cell reproduction, normal growth, and for the maintenance of normal erythropoiesis.

Pharmacokinetics

Absorption: Vitamin B₁₂ is irregularly absorbed from the distal small intestine following oral administration. Vitamin B₁₂ absorption is an active process that requires gastric intrinsic factor. Intrinsic factor is a glycoprotein secreted by the gastric mucosa. Passive diffusion through the intestinal wall can occur but large amounts of Vitamin B₁₂ are required (i.e. >1 mg). Following oral doses less than 3 mcg, peak plasma concentrations are not reached for 8 to 12 hours because the vitamin is transiently retained in the wall of the lower ileum.

Vitamin B₁₂ is rapidly absorbed from Intramuscular (IM) and Subcutaneous (SC) sites of injection; peak plasma concentrations are reached within 1 hour after IM injection.

Distribution: Vitamin B₁₂ is distributed into the liver, bone marrow, and other tissues, including the placenta. At birth, the blood concentration of Vitamin B₁₂ in neonates is 3 to 5 times that of the mother.

Total body stores of Vitamin B₁₂ in healthy individuals are estimated to range from 1 to 11 mg, with an average of 5 mg; 50 to 90 % is stored in the liver. Vitamin B₁₂ is believed to be converted to coenzyme form in the liver and is probably stored in tissues in this form.

Elimination: Following IM administration of 0.1 to 1 mg of cyanocobalamin, 50 to 90 % of the dose may be excreted in urine by glomerular filtration within 48 hours, with the major portion being excreted in the first 8 hours. Hydroxocobalamin is more highly protein bound and is retained in the body longer than cyanocobalamin; however, it is not more effective in normalizing the hematocrit.

Because hydroxocobalamin may cause formation of antibodies to hydroxocobalamin- transcobalamin II complex, cyanocobalamin is usually the preferred form of vitamin B₁₂.

INDICATIONS AND CLINICAL USE

Vitamin B₁₂ Deficiency: For vitamin B₁₂ deficiency occurring in pernicious anemia with or without neurological complications. Other macrocytic, megaloblastic anemias where etiology

suggests malabsorption of vitamin B₁₂ such as following: gastrectomy, gastric carcinoma, megaloblastic anemia associated with such gastrointestinal disorders as sprue syndrome, blind loops and anastomoses and fish tapeworm.

Note: In macrocytic megaloblastic anemia of pregnancy and sprue syndromes, cyanocobalamin may fail to produce satisfactory response, folic acid being indicated alone or in combination with cyanocobalamin.

The injection is also suitable for use as the flushing dose in the Schilling (Vitamin B₁₂ absorption) test for pernicious anemia.

CONTRAINDICATIONS

Cyanocobalamin Injection USP is contraindicated in patients who have experienced hypersensitivity reactions to the vitamin or to cobalt.

WARNINGS

Patients who have early Leber's disease (hereditary optic nerve atrophy) have been found to suffer severe and swift optic nerve atrophy when treated with Vitamin B₁₂.

Hypokalemia and sudden death may occur when severe megaloblastic anemia is treated intensively. Lack of therapeutic response may be due to infection, uremia, concomitant treatment with chloramphenicol or misdiagnosis.

PRECAUTIONS

A sensitivity history should be obtained from the patient prior to administration of Cyanocobalamin Injection USP; an intradermal test dose is recommended before Cyanocobalamin Injection USP is administered to patients known to be sensitive to cobalamins.

Parenteral administration of cyanocobalamin is the required treatment for originally diagnosed and relapsed pernicious anemia with severe neurologic manifestations. Also in treatment of megaloblastic anemia associated with sprue, supplementation with folic acid is usually necessary and parenteral Vitamin B₁₂ may be required.

If a vitamin B₁₂ deficiency is allowed to progress more than 3 months, permanent degenerative spinal cord lesions may occur, such lesions have been observed when folic acid is used as the sole hematopoietic agent.

Patients who have early Leber's disease (hereditary optic nerve atrophy) have been found to suffer severe and swift optic nerve atrophy when treated with Vitamin B₁₂.

Serum potassium concentrations should be monitored during early Vitamin B₁₂ therapy and potassium administered if necessary, since fatal hypokalemia could occur upon conversion of

megaloblastic anemia to normal erythropoiesis with Vitamin B₁₂ as a result of increased erythrocyte potassium requirements. Therapeutic response to Cyanocobalamin Injection USP may be impaired by concurrent infection, uremia, concomitant treatment with chloramphenicol or misdiagnosis.

Cyanocobalamin or hydroxocobalamin should not be administered Intravenous (IV).

Indiscriminated administration of Vitamin B₁₂ may mask the true diagnosis of pernicious anemia. A dietary deficiency of only Vitamin B₁₂ is rare. Multiple vitamin deficiency is expected in any dietary deficiency.

Histamine₂-Receptor Antagonists (cimetidine, ranitidine, nizatidine, famotidine): May potentially cause vitamin B₁₂ deficiency by decreasing gastric acid cleavage of Vitamin B₁₂ from food sources. This may be important in patients with low stores of Vitamin B₁₂ or in patients taking H₂-antagonists for extended periods of time (>2 years).

Special Populations

Pediatrics: Benzyl alcohol contained in some products has been associated with toxicity in newborns. Toxicity appears to have resulted from administration of large amounts of benzyl alcohol (100 to 400 mg/kg daily). Products containing benzyl alcohol should be used cautiously in neonates, especially those who are receiving other benzyl alcohol containing medications.

Pregnant Women: No adverse effects have been reported with ingestion of normal daily requirements during pregnancy.

Nursing Women: Vitamin B₁₂ is distributed into the milk of nursing women in concentrations that approximate the maternal blood Vitamin B₁₂ concentration. No adverse effects have been reported with intake of normal daily requirements during lactation.

ADVERSE REACTIONS

Vitamin B₁₂ is usually nontoxic even in large doses, however, mild transient diarrhea, polycythemia vera, peripheral vascular thrombosis, itching, transitory exanthema, feeling of swelling of the entire body, pulmonary edema and congestive heart failure early in treatment, anaphylactic shock and death have been reported following Vitamin B₁₂ administration.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

DRUG INTERACTIONS

Most antibiotics, methotrexate and pyrimethamine invalidate folic acid and Vitamin B₁₂ diagnostic microbiological blood assays. Chloramphenicol may antagonize the hematopoietic response to Vitamin B₁₂. Hematopoietic response in such patients should be monitored.

Colchicine, aminoglycosides, certain anticonvulsants (e.g. phenytoin, phenobarbital, primidone), para-aminosalicylic acid or excessive alcohol intake for longer than 2 weeks may impair the absorption of Vitamin B₁₂. Vitamin C may destroy Vitamin B₁₂. Patients should avoid ingesting large amounts of vitamin C within 1 hour of oral Vitamin B₁₂ administration.

DOSAGE AND ADMINISTRATION

Administration

Cyanocobalamin is usually administered by Intramuscular or deep subcutaneous injection. If the drug is administered subcutaneously, care should be taken to avoid injection into the dermis or upper subcutaneous tissue. **Because the drug is excreted more rapidly after IV injection, the IV route should be avoided.**

Dosage

In patients with Addisonian (pernicious) anemia, parenteral therapy with Vitamin B₁₂ is the recommended method of treatment and will be required for the remainder of the patient's life. Oral therapy is not dependable. Serum potassium must be watched closely the first 48 hours; and potassium should be replaced if necessary. Reticulocyte plasma count, Vitamin B₁₂ and folic acid levels must be obtained prior to treatment and between the fifth and seventh day of therapy.

In patients with other types of vitamin B₁₂ deficiency due to malabsorption, the malabsorption should be corrected. In all patients a well balanced dietary intake should be prescribed and prior dietary habits should be corrected.

Vitamin B₁₂ Deficiency: For the treatment of vitamin B₁₂ deficiency in adults, the usual IM or subcutaneous dosage of cyanocobalamin is 30 to 100 mcg daily for 5-10 days. Once clinical symptoms have subsided and the blood components have returned to normal, monthly IM maintenance doses of 100 to 200 mcg appear to be sufficient to maintain a normoblastic bone marrow. Dosage should be adjusted as necessary to maintain normal hematologic morphology and an erythrocyte count greater than 4.5 million/nm³.

In the Schilling test, the flushing dose is 1000 mcg.

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.


PHARMACEUTICAL INFORMATION

Proper name: Cyanocobalamin

Chemical name: 5,6-dimethyl-benzimidazolyl cyanocobamide

Molecular formula and molecular weight: $C_{63}H_{88}CoN_{14}O_{14}P$; 1355.4 g/mol

Structural formula:



Physicochemical properties: Crystals or crystalline powder, deep red colored, odorless.

Solubility at about 20°C:

- water, 95-96% ethanol: sparingly soluble
- acetone, chloroform, ethyl ether: practically insoluble

DOSAGE FORMS, COMPOSITION AND PACKAGING

1000 mcg / mL: Each mL contains cyanocobalamin 1000 mcg, sodium chloride 9 mg as tonicity adjusting agent, Benzyl alcohol 15 mg as preservative, sodium hydroxide and hydrochloric acid to adjust pH and water for injection.

Cyanocobalamin Injection USP 1000 mcg/mL is available in 2 mL vials filled with 1 mL of solution. Unopened vials will appear half-filled upon inspection. The product is available in boxes of 10 vials. Each vial is for single use. Discard unused portion

STORAGE AND STABILITY

Store between 15 and 30°C. Preserve in light-resistant containers

REFERENCES

1. Product Monograph for VITAMINE B12 (Cyanocobalamin Injection USP, 1000 mcg / mL), Sandoz Canada Inc., Submission Control Number: 099873, Date of Revision: December 14, 2011.”

If you want more information about Cyanocobalamin Injection USP:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website:

(<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer’s website <http://www.eugia.ca>, or by calling 1-855-648-6681.

This leaflet was prepared by Eugia Pharma Inc.

Date of Preparation: May 18, 2023